Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that azacitidine is recommended as an option for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)